Inflammatory biomarkers in heart failure

John W Petersen1, G Michael Felker

  • 1Division of Cardiovascular Medicine, Duke University Medical Center, Durham, NC, USA.

Insights

Inflammation, marked by cytokines like tumor necrosis factor alpha, is key in heart failure. Inflammatory markers show promise as heart failure biomarkers and potential therapeutic targets.

Area of Science:

  • Cardiology
  • Immunology
  • Biochemistry

Background:

  • The cytokine hypothesis posits inflammation's critical role in heart failure development and progression.
  • Circulating inflammatory markers such as tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), and C-reactive protein (CRP) are implicated in heart failure.
  • These markers may serve diagnostic, prognostic, and therapeutic response evaluation roles in heart failure patients.

Purpose of the Study:

  • To review the evidence supporting inflammatory markers as biomarkers in heart failure.
  • To analyze the potential of inflammatory cytokines as therapeutic targets for heart failure.
  • To discuss the ongoing research into modulating the immune response for heart failure treatment.

Main Methods:

  • Systematic review of existing literature on inflammation and heart failure.
  • Analysis of data on the utility of inflammatory markers (TNF-α, IL-6, CRP) in heart failure diagnosis and prognosis.
  • Evaluation of studies investigating cytokine-targeted therapies and immune modulation in heart failure.

Main Results:

  • Inflammatory markers demonstrate potential utility in diagnosing heart failure, predicting prognosis, and monitoring treatment response.
  • Therapies directly targeting specific cytokines, like TNF-α, have yielded disappointing results to date.
  • Despite setbacks, research continues to explore the therapeutic potential of immune response modulation in heart failure.

Conclusions:

  • Inflammatory markers are valuable tools for understanding and managing heart failure.
  • Targeting specific cytokines has faced challenges, but broader immune modulation remains a promising area for heart failure therapy.
  • Further research is warranted to fully elucidate the therapeutic potential of targeting the inflammatory pathways in heart failure.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...